Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata
Eman Ali, Rabia Owais, Ayesha Sheikh, Asim Shaikh
Abstract
Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.
Topics & Concepts
MedicineAlopecia areataFood and drug administrationDermatologyRheumatoid arthritisClinical trialMedical prescriptionOff-label useCoronavirus disease 2019 (COVID-19)Intensive care medicinePharmacologyInternal medicineDiseaseInfectious disease (medical specialty)Hair Growth and DisordersBody Contouring and SurgeryDermatologic Treatments and Research